592 related articles for article (PubMed ID: 32295104)
1. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders?
Chakaroun RM; Massier L; Kovacs P
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295104
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes.
Scheithauer TPM; Rampanelli E; Nieuwdorp M; Vallance BA; Verchere CB; van Raalte DH; Herrema H
Front Immunol; 2020; 11():571731. PubMed ID: 33178196
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies.
Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
Gastroenterology; 2021 Jan; 160(2):573-599. PubMed ID: 33253685
[TBL] [Abstract][Full Text] [Related]
4. Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases.
Massier L; Blüher M; Kovacs P; Chakaroun RM
Front Endocrinol (Lausanne); 2021; 12():616506. PubMed ID: 33767669
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of intestinal microbiota and microbial metabolites in metabolic control.
Herrema H; IJzerman RG; Nieuwdorp M
Diabetologia; 2017 Apr; 60(4):613-617. PubMed ID: 28013341
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota, obesity and metabolic disorders.
Federico A; Dallio M; DI Sarno R; Giorgio V; Miele L
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):337-344. PubMed ID: 28927249
[TBL] [Abstract][Full Text] [Related]
7. Deletion of intestinal epithelial AMP-activated protein kinase alters distal colon permeability but not glucose homeostasis.
Olivier S; Pochard C; Diounou H; Castillo V; Divoux J; Alcantara J; Leclerc J; Guilmeau S; Huet C; Charifi W; Varin TV; Daniel N; Foretz M; Neunlist M; Salomon BL; Ghosh P; Marette A; Rolli-Derkinderen M; Viollet B
Mol Metab; 2021 May; 47():101183. PubMed ID: 33548500
[TBL] [Abstract][Full Text] [Related]
8. Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier.
Van Hul M; Geurts L; Plovier H; Druart C; Everard A; Ståhlman M; Rhimi M; Chira K; Teissedre PL; Delzenne NM; Maguin E; Guilbot A; Brochot A; Gérard P; Bäckhed F; Cani PD
Am J Physiol Endocrinol Metab; 2018 Apr; 314(4):E334-E352. PubMed ID: 28874357
[TBL] [Abstract][Full Text] [Related]
9. Role of the gut microbiota in type 2 diabetes and related diseases.
Yang G; Wei J; Liu P; Zhang Q; Tian Y; Hou G; Meng L; Xin Y; Jiang X
Metabolism; 2021 Apr; 117():154712. PubMed ID: 33497712
[TBL] [Abstract][Full Text] [Related]
10. [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R
Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
[TBL] [Abstract][Full Text] [Related]
11. Metal transporter SLC39A14/ZIP14 modulates regulation between the gut microbiome and host metabolism.
Mitchell SB; Thorn TL; Lee MT; Kim Y; Comrie JMC; Bai ZS; Johnson EL; Aydemir TB
Am J Physiol Gastrointest Liver Physiol; 2023 Dec; 325(6):G593-G607. PubMed ID: 37873588
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes.
Bleau C; Karelis AD; St-Pierre DH; Lamontagne L
Diabetes Metab Res Rev; 2015 Sep; 31(6):545-61. PubMed ID: 25352002
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome, endocrine control of gut barrier function and metabolic diseases.
Régnier M; Van Hul M; Knauf C; Cani PD
J Endocrinol; 2021 Feb; 248(2):R67-R82. PubMed ID: 33295880
[TBL] [Abstract][Full Text] [Related]
14. [Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?].
Genser L; Poitou C; Brot-Laroche É; Rousset M; Vaillant JC; Clément K; Thenet S; Leturque A
Med Sci (Paris); 2016 May; 32(5):461-9. PubMed ID: 27225918
[TBL] [Abstract][Full Text] [Related]
15. Diet-microbiota interactions as moderators of human metabolism.
Sonnenburg JL; Bäckhed F
Nature; 2016 Jul; 535(7610):56-64. PubMed ID: 27383980
[TBL] [Abstract][Full Text] [Related]
16. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota in health and disease: an overview focused on metabolic inflammation.
Nagpal R; Kumar M; Yadav AK; Hemalatha R; Yadav H; Marotta F; Yamashiro Y
Benef Microbes; 2016; 7(2):181-94. PubMed ID: 26645350
[TBL] [Abstract][Full Text] [Related]
18. Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier.
Usuda H; Okamoto T; Wada K
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299233
[TBL] [Abstract][Full Text] [Related]
19. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders.
Macchione IG; Lopetuso LR; Ianiro G; Napoli M; Gibiino G; Rizzatti G; Petito V; Gasbarrini A; Scaldaferri F
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8075-8083. PubMed ID: 31599433
[TBL] [Abstract][Full Text] [Related]
20. Beneficial actions of microbiota-derived tryptophan metabolites.
Galligan JJ
Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 29341448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
